Jay Shubrook, DO, FAAFP, FACOFP, discusses Type 1 diabetes (T1D). He delves into the importance of screening, early intervention, and patient-centered care. He also addresses the increasing prevalence in adults and modern technologies that are aiding T1D treatment.

Dr. Shubrook discloses relationships with Abbott, Bayer, and Novo Nordisk as a non-CE consultant and AstraZeneca, Eli Lilly, and Novo Nordisk as an advisory board member. This podcast has been reviewed by non-conflicted physicians to ensure any potential conflicts are mitigated.